Literature DB >> 18061618

Confirmation and extension of the validity of the Multiple Sclerosis Walking Scale-12 (MSWS-12).

Robert W Motl1, Erin M Snook.   

Abstract

OBJECTIVE: The Multiple Sclerosis Walking Scale-12 (MSWS-12) is a 12-item patient-rated measure of the impact of MS on walking. As validation of scores from a measure is an ongoing and evolving process, the provision of additional evidence is warranted that confirms and extends the validity of inferences from scores on the MSWS-12.
METHOD: Participants (N=133) were recruited through support group meetings of the Greater Illinois and Indiana State Chapters of the National Multiple Sclerosis Society, and wore an accelerometer for a seven-day period and completed the MSWS-12 and other outcome measures.
RESULTS: Confirmatory factor analysis indicated that a single-factor model provided an adequate fit for MSWS-12 scores. MSWS-12 scores demonstrated strong evidence of internal consistency. The correlations between MSWS-12 scores with scores from other scales, including an accelerometer, were consistent with our a priori hypotheses.
CONCLUSION: We provide evidence that both confirms and extends the validity of inferences from scores of the MSWS-12 as a measure of the impact of MS on walking in a community-based sample of individuals with MS.

Entities:  

Mesh:

Year:  2007        PMID: 18061618     DOI: 10.1016/j.jns.2007.11.003

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  25 in total

1.  Psychometric performance of a generic walking scale (Walk-12G) in multiple sclerosis and Parkinson's disease.

Authors:  Stina Bladh; Maria H Nilsson; Gun-Marie Hariz; Albert Westergren; Jeremy Hobart; Peter Hagell
Journal:  J Neurol       Date:  2011-09-29       Impact factor: 4.849

2.  Does a waist-worn accelerometer capture intra- and inter-person variation in walking behavior among persons with multiple sclerosis?

Authors:  Robert W Motl; Jacob J Sosnoff; Deirdre Dlugonski; Yoojin Suh; Myla Goldman
Journal:  Med Eng Phys       Date:  2010-09-26       Impact factor: 2.242

3.  Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world.

Authors:  Myla D Goldman; Robert W Motl; John Scagnelli; John H Pula; Jacob J Sosnoff; Diego Cadavid
Journal:  Neurology       Date:  2013-10-30       Impact factor: 9.910

4.  Evaluating walking in patients with multiple sclerosis: which assessment tools are useful in clinical practice?

Authors:  Francois Bethoux; Susan Bennett
Journal:  Int J MS Care       Date:  2011

5.  Possible clinical outcome measures for clinical trials in patients with multiple sclerosis.

Authors:  Myla D Goldman; Robert W Motl; Richard A Rudick
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

6.  Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale.

Authors:  Myla D Goldman; Melanie D Ward; Robert W Motl; David E Jones; John H Pula; Diego Cadavid
Journal:  Mult Scler       Date:  2016-12-07       Impact factor: 6.312

7.  Accelerometry and its association with objective markers of walking limitations in ambulatory adults with multiple sclerosis.

Authors:  Robert W Motl; Deirdre Dlugonski; Yoojin Suh; Madeline Weikert; Bo Fernhall; Myla Goldman
Journal:  Arch Phys Med Rehabil       Date:  2010-12       Impact factor: 3.966

8.  Treatment of walking impairment in multiple sclerosis with dalfampridine.

Authors:  Andrew R Blight
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

9.  Walking impairment in patients with multiple sclerosis: exercise training as a treatment option.

Authors:  Robert W Motl; Myla D Goldman; Ralph H B Benedict
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-16       Impact factor: 2.570

10.  The e-MSWS-12: improving the multiple sclerosis walking scale using item response theory.

Authors:  Matthew M Engelhard; Karen M Schmidt; Casey E Engel; J Nicholas Brenton; Stephen D Patek; Myla D Goldman
Journal:  Qual Life Res       Date:  2016-06-24       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.